Record ID: MS-N079 · Family: Nutrition and dietary patterns / survivorship · Clinical question: Do intensive low-fat or high-vegetable dietary programs reduce recurrence or death after early breast cancer?

Evidence label: Mixed randomized evidence: WHEL was null; WINS reported an interim relapse signal alongside modest weight loss, so the independent effect of fat reduction remains uncertain.

Evidence at a glance

• Benefit: No benefit in WHEL; WINS reported fewer relapse events in its interim analysis.
• Certainty: Moderate that the WHEL program did not reduce events; low-to-moderate for a WINS-specific benefit because weight changed and the analysis was interim.
• Risk: Nutritional inadequacy or unwanted weight loss if restriction is poorly planned; otherwise food-based programs were generally feasible.
• Cancer control: Not established as an anticancer treatment and not a substitute for surgery, radiation, endocrine therapy or systemic therapy.

What was studied

The WHEL randomized trial enrolled 3,088 women previously treated for early-stage invasive breast cancer. Its intensive counseling program promoted a very high intake of vegetables, fruit and fiber with low dietary fat; the comparison group received printed dietary guidance. Mean follow-up was 7.3 years.

The WINS randomized 2,437 women with resected early-stage breast cancer to a low-fat dietary intervention or usual dietary advice. At 12 months, reported fat intake was 33.3 versus 51.3 g/day, and mean body weight was about 6 lb lower in the intervention group.

What the results show

In WHEL, invasive breast-cancer events occurred in 256 women (16.7%) assigned to the intervention and 262 (16.9%) assigned to comparison care: adjusted HR 0.96 (95% CI 0.80–1.14). Deaths were 155 (10.1%) versus 160 (10.3%): HR 0.91 (95% CI 0.72–1.15).

In the WINS interim report, relapse events occurred in 96 of 975 women (9.8%) in the dietary group and 181 of 1,462 (12.4%) controls: adjusted Cox HR 0.76 (95% CI 0.60–0.98). The stratified log-rank P value was 0.077, while the adjusted Cox-model P value was 0.034. These discordant randomized results argue against treating “low fat” as one uniform intervention.

Important limits

• The programs differed in targets, counseling intensity, comparison care and weight change.
• WINS cannot cleanly separate dietary fat reduction from modest weight loss or other behavior changes.
• Neither trial tests a supplement, ketogenic diet or a short-term “detox.”
• The evidence applies to survivorship after treatment, not to shrinking an existing tumor.
• Funding and conflict details were not fully re-extracted for every historical report in this pass.

Safety and practical context

A food-based survivorship plan should protect protein, calcium, vitamin D, iron and overall energy intake. People losing weight unintentionally, living with bowel symptoms or receiving active treatment need individualized nutrition review.

Questions for the care team

• Is weight loss intended, safe and monitored in my situation?
• Will the plan meet protein and micronutrient needs during treatment or recovery?
• Does my cancer subtype or current therapy change the nutrition goal?
• Which outcome matters here—cardiometabolic health, quality of life or recurrence risk?

Sources checked

• WHEL randomized trial, JAMA 2007 (PMID 17635889)
• WINS interim randomized results, JNCI 2006 (PMID 17179478)

Funding and conflicts: Both were large cooperative dietary trials with institutional and grant support; complete sponsor and author-disclosure details should be checked in the original reports before secondary use.

Last literature search: October 20, 2026 · Record appraisal: October 20, 2026

Educational information only. This record is not a prescription and does not replace advice from the oncology team, registered dietitian or oncology pharmacist.